Bipolar Clinical Trial
Official title:
Genetic Association Study Between Single Nucleotide Polymorphisms (SNPs) and Cognitive Performance in Young Bipolar Type I Patients: LICAVALGENE
This is a genetic association study of cognitive impairment in young bipolar disease type I patients without medications in mania, depression, hypomania or mixed states.
Introduction:
Cognitive impairment in bipolar disease (BD) patients is common and recent data suggests
that it may be an endophenotype of the disease as it differs individually, persists during
periods of euthymia and co segregates in families of BD patients. Cognition is a complex
trait and is therefore likely to be underpinned by many genes, each with a relatively small
effect. Performance in each domain of the neuropsychological assessment can be statistically
linked to the functional activity of particular protein and by extension to the genetic
variants accounting for theses functional differences.
Methods:
80 patients with BD type I (SCID DSM-IV), age from 18 to 35 years old, currently on mania,
depression, hypomania or mixed state after medication wash out will be submitted to complete
neuropsychological evaluation and genotyped for COMT (val158met, rs165599, -287, rs737865),
ApoE (epsilon 4) and BDNF (val66met)and 80 healthy controls.
;
Observational Model: Case Control, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT02133170 -
"Mindfulness vs Psychoeducation in Bipolar Disorder"
|
N/A | |
| Completed |
NCT02189057 -
A Pharmacokinetic/Pharmacodynamic Genetic Variation Treatment Algorithm Versus Treatment As Usual for Management Of Depression
|
N/A | |
| Completed |
NCT00666432 -
Bipolar and Schizophrenia Consortium for Parsing Intermediate Phenotypes
|
||
| Completed |
NCT00300820 -
Perspectives of Individuals With Bipolar Disorder and Siblings of Individuals With Bipolar Disorder; A Telephone Interview Study
|
N/A | |
| Completed |
NCT02184767 -
Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication
|
Phase 1 | |
| Terminated |
NCT01131559 -
Adjunctive Lisdexamfetamine (LDX) in Bipolar Depression
|
Phase 3 | |
| Recruiting |
NCT01047215 -
Heart Rate Changes in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine
|
Phase 4 |